Lineage Cell Therapeutics, Inc.
LCTX- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000876343
No open-market purchases or sales by Lineage Cell Therapeutics, Inc. insiders were filed in the last 90 days; 131 institutions reported holding it in 13F filings for Q2 2026, worth $152.7M in total; no superinvestor holds it.
Q4 2021 vs. Q3 2021
How the institutions holding Lineage Cell Therapeutics, Inc. changed between Q3 2021 and Q4 2021.
All holders in Q4 2021All holders in Q3 2021
| Measure | Q3 2021 | Q4 2021 | Change |
|---|---|---|---|
| Holders | 115 | 124 | +9 |
| Shares | 75.8M | 74.4M | −1.45M (−1.9%) |
| Value | $191.7M | $182.0M | −$9.76M (−5.1%) |
New holders (25)
Institutions that held Lineage Cell Therapeutics, Inc. at the end of Q4 2021 but not at the end of Q3 2021.
Sold out (16)
Institutions that held Lineage Cell Therapeutics, Inc. at the end of Q3 2021 and filed for Q4 2021 without it.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| Bank of Montreal | 359,381 | $913.0K |
| Rafferty Asset Management, LLC | 193,756 | $488.0K |
| Laidlaw Wealth Management LLC | 104,841 | $264.0K |
| Two Sigma Securities, LLC | 96,762 | $244.0K |
| Winton Group Ltd | 62,869 | $158.0K |
| Thrivent Financial for Lutherans | 42,533 | $107.0K |
| Sightline Wealth Advisors, LLC | 14,958 | $38.0K |
| Group One Trading, L.P. | 13,807 | $35.0K |
| IFP Advisors, Inc | 11,077 | $28.0K |
| E Fund Management Co., Ltd. | 11,095 | $28.0K |
| Glen Eagle Advisors, LLC | 500 | $1.26K |
| Godsey & Gibb Associates | 500 | $1.00K |
| O'Shaughnessy Asset Management, LLC | 396 | $1.00K |
| Community Bank, N.A. | 508 | $1.00K |
| Assetmark, Inc | 9 | $0 |
| Gerber Kawasaki Wealth & Investment Management | 1 | – |